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ABSTRACT
The prevalence of diabetes mellitus (DM), a chronic disease with hyperglycemia and impaired immune function, is increasing 
worldwide. Progression from impaired glucose tolerance (IGT) to type 2 DM has recently become a target for early intervention. The 
fruiting bodies (FB) and submerged culture mycelium (CM) of Tremella mesenterica, an edible and medicinal mushroom, have been 
demonstrated to have antihyperglycemic and immunomodulatory activities in type 1 DM rats. Herein, we investigated the effects of 
acidic polysaccharide glucuronoxylomannan (GX) extracted from CM on the immunocyte responses. Male Wistar rats were injected 
with streptozotocin (65 mg/kg) plus nicotinamide (200 mg/kg) for the induction of IGT, and gavaged daily with vehicle, FB, CM, or GX 
(1 g/kg/day). Rats injected with saline and gavaged vehicle were used as controls. Two weeks later, peripheral blood leukocytes (PBLs) 
and splenocytes were collected. Ingestion of FB, CM, and GX significantly decreased blood glucose levels in the postprandial period 
and in oral glucose tolerance test, and partially reversed T‑splenocytic proliferation in IGT rats. CM significantly decreased T‑helper 
lymphocytes in the PBLs and B‑splenocytes. In addition, FB, CM, and GX significantly reversed the IGT‑induced decreases in tumor 
necrosis factor‑α production; GX significantly increased interleukin‑6 production in T‑lymphocytes in the PBLs and splenocytes; and 
CM and GX significantly reversed IGT‑induced decrease in interferon‑γ production in T‑lymphocytes in the spleen. In conclusion, FB, 
CM, and acidic polysaccharide GX of T. mesenterica may increase T‑cell immunity via the elevation of proinflammatory and T‑helper 
cytokine production in rats with impaired glucose tolerance.
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INTRODUCTION
The World Health Organization (WHO) indicated that ap‑
proximately 3.4 million people died from the consequences of 
high fasting blood glucose, the major symptom of diabetes mel‑
litus (DM), in 2010 and 347 million people have DM in 2013 
worldwide.[1,2] The economic costs of DM are increasing globally, 
which cause a heavy health and economic burden.[3] Therefore, 
several countries have made and are still making great efforts on 
preventing and delaying the onset of DM, especially type 2 DM. 
Type 2 DM comprises 90% of people with DM around the world.[1] 
Before being diagnosed, almost all of the type 2 DM patients suffer 
from impaired glucose tolerance (IGT) for years.[4]
DM patients have abnormal carbohydrate, fat, and protein 
metabolism.[2] It has been reported that type 2 DM and IGT patients 
have increased blood tumor necrosis factor alpha (TNF)‑α[5] and 
interleukin (IL)‑6,[6] suggesting a cytokine‑mediated acute‑phase 
reaction inflammation.[7,8] In addition, the peripheral blood leu‑
kocytes (PBLs) obtained from type 2 DM patients were found 
to have reduced proliferative response to mitogens, suggesting 
an impaired cell‑mediated immunity.[9,10] T cells in type 2 DM 
patients were toward proinflammatory subsets that may promote 
chronic inflammation in type 2 DM through elevated cytokine 
production.[11] These results implied that patients with type 2 DM 
have altered immune function.
The use of dietary supplements, nutraceuticals, and functional 
foods has become a popular approach to prevent and delay the 
development of type 2 DM, which may have the potential to 
eliminate the health and economic burden of the disease. Growing 
evidence suggests that mushroom polysaccharides have vari‑
ous biological activities, such as antitumor,[12] antidiabetic,[13] 
anti‑inflammatory,[14] immunomodulatory,[15,16] and steroidogenic 
activities.[17] Tremella mesenterica (Heterobasidiomycetes), a 
yellow brain jelly mushroom, is a popular edible and medicinal 
mushroom in Asia. Its pharmacologically active polysaccharides 
make up 60‑70% structural fruiting body polysaccharides and up 
to 20% of polysaccharides are glucuronoxylomannan (GX).[18] 
We previously demonstrated that ingestion of T. mesenterica 
fruiting bodies (FB), submerged culture mycelium (CM), and 
CM derived GX significantly attenuated the increases of blood 
glucose levels in 2‑h postprandial period and in an oral glucose 
tolerance test (OGTT) in IGT rats.[19] In addition, T. mesenterica 
FB may increase peripheral cell‑mediated immunity and CM 
may decrease proinflammatory and T‑helper (Th) 1 cytokine 
production in type 1 DM rats.[20] However, the effects of T. mes‑
enterica on immune function in type 2 DM and IGT have not 
been investigated.
In the present study, we aimed to investigate whether 
T. mesenterica may attenuate the altered immunity in IGT us‑
ing a rat model injected with nicotinamide and streptozotocin, a 
cytotoxic agent that specifically affects pancreatic b‑cells.[21] To 
evaluate changes in systemic and tissue‑specific immunity, the 
subset distribution of immunocytes, and immunocytic prolifera‑
tion, the peripheral blood and spleen were collected from IGT rats 
that ingested FB, CM, and GX of T. mesenterica for 2 weeks. The 
levels of cytokine production by the PBLs and splenocytes with 
and without mitogen stimulation were also determined.
MATERIALS AND METHODS
Animals and experimental design
Male Wistar rats (Animal Center of National Taiwan Univer‑
sity, Taipei, Taiwan) weighing approximately 200 g (~6 weeks old, 
n = 50) were housed in individual stainless steel cages with free 
access to water and a normal chow diet (AIN‑76; ICN Biomedicals 
Inc., Cleveland, OH) in a room maintained at 22°C on a 12:12‑h 
light: dark cycle. The animal facilities and protocols were approved 
by the Institutional Animal Care and Use Committee (IACUC) in 
Changhua Christian Hospital, Changhua, Taiwan.
After the rats were adapted for 7 days, they were fasted over‑
night, weighed, and divided into normal and IGT groups. Under 
light ether anesthetization, normal rats were intraperitoneally and 
intravenously injected with saline (n = 8). IGT rats (n = 42) were 
intraperitoneally injected with nicotinamide (200 mg/kg, Sigma 
Chemical Co., St. Louis, MO, USA) 15 min before the injection of 
streptozotocin (STZ, 65 mg/kg of body weight, Sigma Chemical 
Co., St. Louis, MO, USA) via tail vein. Five days later, animals 
were fed with a chow diet at 0900 h to 1100 h and blood was 
drawn via the tail vein at 1300 h to measure the 2‑h postprandial 
blood glucose concentrations. Rats having 2‑h postprandial blood 
glucose concentrations higher than 250 mg/100 ml were considered 
as IGT and were divided into NTZ, NFB, NCM, and NGX groups. 
The final sample size was nine rats per group, with 85.7% rate of 
success in the induction of IGT.
Animals in the CON, NTZ, NFB, NCM, and NGX groups were 
intragastrically treated with vehicle, vehicle, FB, CM, and acidic 
polysaccharide GX for 2 weeks (1 g/kg/day on days 1‑14), respec‑
tively. The vehicle provided equal amounts of the major compo‑
nents of CM, including protein (22.7%, casein), carbohydrate (56%, 
corn starch), and fiber (16.3%, cellulose). In order to pass through 
the feeding syringe and needle smoothly, the pulverized FB, CM, 
GX, and vehicles were mixed with distilled water to form paste 
mixtures (0.25 g/2 ml) for bolus feeding. The intragastric treatments 
were administered before providing the chow diet.
During the experimental period, body weights of the rats were 
measured two times per week and the amounts of food and water 
intake were measured daily. On day 15, animals were executed 
after being anesthetized by intramuscular injections of ketamine 
(100 mg/kg/day) and xylazine (10 mg/kg/day). After the animals 
became thoroughly unconscious, blood was collected by cardiac punc‑
ture, and plasma and blood cells were isolated for various assays. The 
spleens were dissected, weighed, and processed for further analyses.
Preparation of FB, TM, and GX
T. mesenterica Retz. Fr. (CBS 101939) FB were col‑
lected in Israel on the dead wood of Quercus calliprinos Webb. 
The basidiospore prints were obtained from a fresh fruiting body 
placed under a sterile Petri dish in a moist chamber with slowly 
decreasing humidity and were used for the submerged culture, as de‑
scribed by Reshetnikov et al.[18] Culture mycelia were obtained from 
a submerged cultivation of fermentation, and acidic polysaccharide 
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GX was extracted and purified by Amberlite IR‑120 (H+‑form) 
chromatography column, 10% aqueous cetyl pyridinium chlo‑
ride, 10% sodium chloride, and ethanol.[18] The relative content of 
acidic polysaccharide GX in the TM was approximately 50%. The 
components of TM included glycogen (6%), dietary fiber (16.3%), 
mineral (5%), protein (20%), and free amino acid (2.7%).
Blood glucose and OGTT
The 2‑h postprandial blood glucose concentrations were 
measured prior to the induction of IGT, 5 days after the induc‑
tion, and on days 0 and 14. After overnight fasting on day 10, the 
OGTT was performed for the animals. Briefly, glucose (2 g/kg 
body weight) was intragastrically administered as a 30% solution 
to animals. Blood samples were collected sequentially from the 
tail vein before, and 10, 20, 30, 60, 90, and 120 min after glucose 
administration. The blood glucose concentrations were determined 
using MediSense Card Blood Glucose Testing Systems (Precision 
Plus Electrodes; Abbott Laboratories, Bedford, MA, USA), using 
an electrochemical detection technique accompanied with glucose 
oxidase method.
Serological analysis and plasma cytokines
The numbers of circulating white blood cells (WBC) were 
determined using a hematology analyzer (GEN; Coulter Inc., 
Miami, FL, USA). Plasma concentrations of TNF‑α, interfer‑
on (IFN)‑γ, and IL‑6 were measured using commercially available 
enzyme‑linked immunosorbent assays (ELISA; R&D System, 
Minneapolis, MN, USA) with sensitivities 5, 10, and 18 pg/
ml, respectively. All the samples for ELISA measurements were 
analyzed in one assay in duplicate. The inter‑assay coefficients of 
variance were below 10%.
Analysis of immunocyte subpopulation
For the immunocyte subpopulation in the PBLs, ethylene‑
diaminetetraacetic acid (EDTA)‑whole blood was reacted with 
appropriate antibodies directed against cell‑surface antigens and 
analyzed by flow cytometer, as described in our previous study.[20] 
For splenocytes, single‑cell suspensions of splenocytes were pre‑
pared and 1 × 106 splenocytes were used to be labeled with the 
appropriate antibodies.
The cell‑surface markers for determination of immuno‑
cyte subpopulations included CD3‑fluorescein isothiocya‑
nate (FITC, clone G4.18), CD3‑phycoerythrin (PE, clone G4.18), 
CD4‑PE (clone OX‑35), and CD8b‑FITC (clone 341) for T cells 
and CD45RA‑PE (clone OX‑33) and IgM‑FITC (clone G53‑238) 
for B cells. FITC‑conjugated mouse IgG1 (clone A112‑2) and 
PE‑conjugated mouse IgG3 (clone A112‑3) were used as nonspe‑
cific isotype control antibodies. Immunofluorescence detection of 
cell subsets was performed using a Becton–Dickinson  FASCScan 
flow cytometer with excitation capabilities at 488 nm for the mea‑
surements of FITC‑ and PE‑conjugated mouse anti‑rat monoclonal 
antibodies (BD Biosciences, San Jose, CA, USA).
Analysis of immunocyte function
The proliferation of splenocytes in vitro in response to mi‑
togens such as concanavalin A (Con A, a T‑cell mitogen) and 
lipopolysaccharide (LPS, a B‑cell and macrophage/monocyte 
mitogen) was measured. Splenocytes (2.5 × 105 cells) were plated 
in triplicate with 50 ml of RPMI 1640 medium with or without Con 
A (5 mg/ml) and LPS (5 mg/ml). After incubation at 37°C in 5% CO2 
for 36 h, cell proliferation was determined by the MTS [3‑(4,5‑di‑
methylthiazol‑2‑yl)‑5‑(3‑carboxymethoxyphenyl)‑2‑(4‑sul‑
fophenyl)‑2H‑tetrazolium, inner salt; MTS] method (CellTiter 96® 
aqueous one solution; Promega, Madison, WI, USA). The stimula‑
tion index of cell proliferation was calculated from the absorbance 
of splenocytes cultured with mitogen at 490 nm divided by that 
of those cultured in RPMI 1640 medium alone.
The PBLs and splenocytes were plated in triplicate with RPMI 
1640 medium with or without LPS (5 mg/ml) and Con A (5 mg/ml) 
and cultured at 37°C in 5% CO2 for 18 h and the supernatants 
were removed by centrifugation and stored at –80°C. The cy‑
tokine production of TNF‑α, IFN‑γ, and IL‑6 in the PBLs and 
splenocytes (5 × 106 cells) was measured using ELISA. Samples 
were analyzed in one assay in duplicate.
Statistical analysis
The differences among all groups were compared by one‑way 
analysis of variance (ANOVA) using the SAS general linear mod‑
els program. Values were represented as the means ± SEM. The 
protective least‑significant difference (LSD) technique was used as 
the post‑hoc analysis to compare the differences between groups 
when ANOVA indicated an overall significant treatment effect.
RESULTS
Body weight, food and water intake, and blood glucose
The body weight gains during the experimental period were 
not significantly different among groups [Figure 1a]. However, the 
amount of weekly food intake was significantly increased in the 
NTZ (150.3 ± 6.9 g) and NCM (134.0 ± 5.9 g) groups compared 
to the CON group (117.9 ± 3.1 g). The amount of weekly water 
intake was significantly increased in the NTZ (344.9 ± 56.9 ml) 
group compared to the CON group (231.4 ± 17.4 ml). Neither 
FB nor GX significantly altered the amount of food and water 
intake in IGT rats.
The 2‑h postprandial blood glucose concentrations on day 0 
were significantly higher in IGT rats (310.8 ± 15.1 mg/100 ml) than 
in normal rats (113.1 ± 4.2 mg/100 ml), but there was no significant 
difference among the NTZ, NFB, NCM, and NGX groups. The 2‑h 
postprandial blood glucose levels on day 14 were significantly in‑
creased in the NTZ group compared to the CON group [Figure 1b]. 
Ingestion of FB, TM, and GX significantly attenuated the increases 
in the 2‑h postprandial blood glucose levels.
In the OGTT, blood glucose concentrations at 0 (i.e. the 
fasting blood glucose), 10, 20, 30, 60, 90, and 120 min were 
significantly higher in the NTZ group than those in the CON 
group [Table 1]. The NFB, NCM, and NGX groups had signifi‑
cantly lower blood glucose at 10, 20, 30, 60, 90, and 120 min, 
compared to the NTZ group. The blood glucose response in 
OGTT, as shown in area under the curve (AUC), was signifi‑
cantly increased in IGT rats and was significantly attenuated by 
ingestion of FB, TM, and GX [Figure 1c].
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Plasma concentrations of cytokines
Plasma concentrations of TNF‑α, IFN‑γ, and IL‑6 are shown in 
Figure 2. There were no significant differences in plasma TNF‑α 
and IFN‑γ concentrations among groups. The NFB and NGX groups 
had significantly lower plasma IL‑6 concentrations, compared to 
the CON group. However, ingestion of FB, TM, and GX had no 
significant effect on the plasma IL‑6 concentration in IGT rats.
Immunocyte subpopulation
There was no significant difference in the circulating num‑
bers of WBC among groups (data not shown). In PBLs, there 
were no significant differences in the percentages of total T 
cells (CD3+, data not shown), Th cells (CD3+ CD4+), T‑suppressor 
cells (CD3+ CD8b+), and mature B cells (CD45RA+IgM+) be‑
tween the CON and NTZ groups [Table 2]. However, the NCM 
group had significantly decreased percentage of Th cells than 
the CON and NTZ groups. In addition, NCM and NGX groups 
had significantly decreased percentages of T‑suppressor cells, 
compared to the CON group. Ingestion of FB, TM, and GX did 
not have significant impact on the mature B cells.
There was no significant difference in the spleen weights 
among groups (data not shown). In the splenocytes, the NTZ, NFB, 
and NCM groups had 20‑25% increases in the percentages of Th 
cells, compared to the CON group. The percentages of T‑suppres‑
sor cells in the splenocytes were not significantly different among 
groups. However, the NCM group had significantly decreased 
mature B cells in the splenocytes, compared to the CON and 
NTZ groups.
Splenocytic proliferation
The numbers of splenocytes were not significantly dif‑
ferent among groups [Figure 3a]. To evaluate the function of 
splenocytes, Con A and LPS were used as mitogens to stimulate 
the proliferation of T and B cells/macrophages in the spleno‑
cytes. The results showed that the NTZ group had significantly 
decreased stimulation index in response to Con A [Figure 3b] but 
not LPS [Figure 3c], compared to the CON group. Ingestion of 
FB, TM, or GX had no significant impact on the proliferation of 
splenocytes derived from IGT rats.
Figure 1. (a) Body weight gain from day 0 to day 14, (b) blood glucose 
concentrations in the 2‑h postprandial period, and (c) blood glucose 
response in OGTT shown as area under the curve (AUC) in normal and 
IGT rats. Values are expressed as the means ± SEM (n = 8‑9 per group). 
Differences were assessed using one‑way ANOVA, followed by post‑hoc 
tests of least significant difference (LSD). *P < 0.05 vs. CON group; 
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Cytokine production by immunocytes
In the PBLs, the unstimulated and Con A‑ and LPS‑stimulated 
production of TNF‑α [Table 3] was significantly decreased in the 
NTZ group compared to the CON group. FB and TM ingestion 
significantly reversed these IGT‑induced decreases in TNF‑α 
production, and GX ingestion significantly reversed the de‑
creases in the unstimulated and Con A‑stimulated production. 
The production of IFN‑γ with or without stimulations was not 
significantly different among groups. The unstimulated and Con 
A‑stimulated production of IL‑6 was significantly greater in the 
NFB and NGX groups than in the CON and NTZ groups. The 
IGT‑decreased IL‑6 production in LPS‑stimulated PBLs was fur‑
ther decreased by the TM ingestion, whereas it was significantly 
reversed by the GX ingestion.
In the splenocytes, the unstimulated production of TNF‑α 
[Table 4] was significantly increased and the Con A‑stimulated 
production of TNF‑α was significantly decreased in the NTZ 
group compared to the CON group. FB and TM ingestion further 
increased the unstimulated TNF‑α production and reversed the 
Con A‑stimulated TNF‑α production in IGT rats. The NCM and 
NGX groups had significantly increased TNF‑α production in 
LPS‑stimulated splenocytes, compared to the CON group. The 
IFN‑γ production of the splenocytes with or without stimulations 
was significantly decreased in the NTZ group compared to the 
CON group. FB, TM, and GX ingestion further decreased the 
unstimulated IFN‑γ production; TM and GX ingestion significantly 
reversed the Con A‑stimulated IFN‑γ production; and GX ingestion 
not only reversed but further increased the LPS‑stimulated IFN‑γ 
production. In addition, the LPS‑stimulated IL‑6 production was 
significantly increased in the NTZ group compared to the CON 
group. The NCM group had 2‑ and 1.6‑fold greater Con A‑ and 
LPS‑stimulated IL‑6 production, respectively, compared to the 
NTZ group. Moreover, the NGX group had approximately four‑
fold greater unstimulated and Con A‑stimulated IL‑6 production, 
compared to the NTZ group.
DISCUSSION
Accumulating evidence suggests that IGT and type 2 DM 
patients have altered or impaired innate immunity and elevated 
circulating proinflammatory cytokines that contributed to insulin 
resistance and infection susceptibility.[22] The antihyperglycemic 
and immunomodulatory effects of T. mesenterica have been dem‑
onstrated in animal studies.[16,19,20] In type 1 DM rats, ingestion of 
CM from T. mesenterica may improve the acute phase response, 
correct the shift in the cytokine profile of the PBLs, and decrease 
the splenocytic proinflammatory response.[20] In the present study, 
ingestion of FB, CM, and GX from T. mesenterica significantly 
reversed the IGT‑induced decreases in TNF‑α production in the 
PBLs and further decreased IFN‑γ and increased IL‑6 production 
in the splenocytes. These results imply that T. mesenterica has 
the potential to modulate innate and cell‑mediated immunity in 
subjects with IGT or prediabetes.
The results of epidemiological studies indicated that IGT 
subjects have an elevated risk of cardiovascular morbidity 
and mortality[23] because they share a low‑grade, proinflammatory 
state with altered immune function.[24‑26] In our study, rats adminis‑
tered with nicotinamide and STZ had significantly increased blood 
glucose in the 2‑h postprandial period [Figure 1b] and during the 
OGTT period [Table 1 and Figure 1c]. However, IGT rats did not 
have significantly increased plasma TNF‑α, IFN‑γ, or IL‑6, unlike 
type 1 DM rats[20] and IGT patients.[24] These differences may be 
because the induction period of this study was not long enough, 
the severity of IGT was not strong enough, and/or the etiology of 
IGT in these rats was different from that of type 1 DM rats and 
IGT patients.
Cell‑mediated immunity is crucial in host defense against intra‑
cellular pathogens. Chang and Shaio[9] reported that the production 
of Th1 cytokines, such as IL‑1b, IL‑2, and IFN‑γ, and the percent‑
ages of total T (CD3+), Th (CD4+), and T‑suppressor (CD8+) 
cells in PBLs were not different between type 2 DM patients and 
Figure 3. (a) The numbers of splenocytes and stimulation indices of cell 
proliferation in splenocytes (5 × 106 cells/ml) cultured with (b) Con A 
and (c) LPS. The stimulation index was calculated as the OD values (at 
490 nm) of the splenocytes cultured with Con A or LPS divided by those 
cultured in medium alone, and multiplied by 100. Values are expressed 
as the means ± SEM (n = 8‑9 per group). Differences were assessed 
using one‑way ANOVA, followed by post‑hoc tests of least significant 
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Table 1. Blood glucose concentrations in the OGTI on day 10 in normal and IGT rats1
Group 0 min 10 min 20 min 30 min 60 min 90 min 120 min
CON 102.9±5.3 143.9±8.1 146.1±5.3 145.1±2.7 141.3±3.8 116.2±4.0 114.0±3.6
NTZ 126.3±13.0* 237.3±29.0* 351.1±33.5* 391.6±30.8* 360.8±28.3* 283.8±34.3* 214.0±36.6*
NFB 107.8±3.7 169.4±8.0‡ 252.0±15.s*‡ 283.4±24.6*‡ 277.8±28.0*‡ 198.4±24.1*‡ 156.3±18.2*‡
NCM 112.8±4.1 185.1±14.3‡ 284.6±14.2*‡ 306.3±15.7*‡ 284.1±14.8*‡ 192.8±11.7*‡ 153.6±7.4*‡
NGX 108.8±3.2 186.0±12.9‡ 284.1±17.3*‡ 332.4±17.6*‡ 306.8±13.3*‡ 211.5±11.7*‡ 156.3±11.9*‡
1Values are means ± SEM. *P<0.05 vs CON group; ‡P<0.05 vs NTZ group in IGT rats by one‑way ANOVA with least significant difference. Unit of blood 
glucose concentration is mg/100 ml. OGTT: glucose tolerance test; IGT: Impaired glucose tolerance; CON: Normal rats with vehicle; NTZ: IGT rats 
with vehicle; NFB: IGT rats with fruiting bodies; NCM: IGT rats with submerged culture mycelium; NGX: IGT rats with acidic polysaccharide 
glucuronoxylomannan
Table 2. Percentages of lymphocyte subsets in the peripheral blood and spleen in normal and IGT rats1
Group Leukocytes % Splenocytes %
CD3+CD4+ CD3+CD8b+ CD45RA+IgM+ CD3+CD4+ CD3+CD8b+ CD45RA+IgM+
CON 22.3±1.6 14.1±0.5 18.1±1.9 19.4±1.1 12.2±1.1 19.5±3.1
NTZ 21.2±1.6 12.0±0.4 15.3±2.1 24.8±1.6* 12.4±1.4 16.2±1.9
NFB 19.2±0.9 13.8±1.3 12.1±1.3 23.9±2.2* 12.4±1.2 18.1±1.9
NCM 15.9±1.4*‡ 11.1±0.6* 16.1±1.8 26.5±1.3* 11.1±0.8 9.6±1.3*‡
NGX 20.5±0.5 10.5±0.6* 19.1±1.5 21.9±1.0 10.1±0.5 17.1±1.7
1Values are means ± SEM. *P<0.05 vs CON group; ‡P<0.05 vs NTZ group in IGT rats by one‑way ANOVA with least significant difference. CD3+CD4+, 
T‑helper cells; CD3+CD8b+, T‑suppressor cells; CD45RA+IgM+, mature B cells. IGT: Impaired glucose tolerance; CON: Normal rats with vehicle; NTZ: 
IGT rats with vehicle; NFB: IGT rats with fruiting bodies; NCM: IGT rats with submerged culture mycelium; NGX: IGT rats with acidic polysaccharide 
glucuronoxylomannan
Table 3. Cytokine productions of peripheral blood leukocytes in normal and IGT rats1
Group TNF‑α pg/ml IFN‑γ pg/ml IL‑6 pg/ml
RPMI 1640 Con A LPS RPMI 1640 Con A LPS RPMI 1640 Con A LPS
CON 131.0±9.4 208.1±15.3 575.7±62.8 15.30±0.61 16.86±0.92 14.96±1.43 53.3±1.9 55.0±1.1 186.0±18.3
NTZ 54.0±2.7* 74.2±6.1* 166.5±10.0* 12.11±0.24 13.42±0.64 12.26±0.28 48.3±2.0 48.8±2.7 69.5±3.3*
NFB 132.4±12.7‡ 159.4±17.0*‡ 271.7±24.3*‡ 11.71±0.24 12.99±0.78 12.10±0.46 82.0±2.6*‡ 66.8±2.5‡ 69.0±3.2*
NCM 122.3±5.7‡ 135.5±7.9*‡ 210.6±10.1*‡ 13.54±0.35 13.26±0.25 13.90±0.34 38.9±2.3* 39.3±2.6* 42.0±2.2*‡
NGX 109.5±4.5‡ 114.7±6.0*‡ 178.6±9.8* 11.90±0.37 12.43±0.30 11.41±0.27 131.7±6.1*‡ 131.0±7.4*‡ 129.3±9.3*‡
1Values are means ± SEM. *P<0.05 vs CON group; ‡P<0.05 vs NTZ group in IGT rats by one‑way ANOVA with least significant difference. Peripheral 
blood leukocytes (5 × 106 cells) were cultured in RPMI 1640 medium with or without concanvalin A (Con A, 5 μg/ml) and lipopolysaccharide (LPS, 
10 μg/ml) at 5% CO2, 37ºC for 18 hours. TNF, tumor necrosis factor; IFN, interferon; IL, interleukin. IGT: Impaired glucose tolerance; CON: Normal rats 
with vehicle; NTZ: IGT rats with vehicle; NFB: IGT rats with fruiting bodies; NCM: IGT rats with submerged culture mycelium; NGX: IGT rats with acidic 
polysaccharide glucuronoxylomannan
Table 4. Cytokine productions of splenocytes in normal and IGT rats1
Group TNF‑α pg/ml IFN‑γ pg/ml IL‑6 pg/ml
RPMI 1640 Con A LPS RPMI 1640 Con A LPS RPMI 1640 Con A LPS
CON 13.1±1.1 111.0±7.8 247.8±10.6 13.88±0.90 103.38±7.32 12.98±1.50 29.0±4.9 32.1±4.0 101.4±7.1
NTZ 30.3±1.9* 30.7±2.4* 303.4±15.0 10.60±0.56* 36.49±3.48* 7.66±0.35* 29.6±2.2 31.9±3.1 194.9±25.7*
NFB 39.5±2.6*‡ 52.3±3.7*‡ 280.0±31.0 7.84±0.98*‡ 36.32±2.04* 6.35±0.11* 37.7±1.6 43.6±3.1 190.0±21.8*
NCM 36.8±1.6*‡ 65.0±6.0*‡ 439.9±35.9* 6.47±0.49*‡ 50.44±2.11*‡ 8.61±0.41* 40.1±2.5* 67.8±3.4*‡ 318.9±23.0*‡
NGX 31.7±2.2* 51.0±2.2*‡ 341.3±17.2* 2.76±0.19*‡ 62.99±3.04*‡ 37.95±0.95*‡ 120.8±5.7•t 126.4±5.7*‡ 170.1±14.2*
1Values are means ± SEM. *P<0.05 vs CON group; ‡P<0.05 vs NTZ group in IGT rats by one‑way ANOVA with least significant difference. Splenocytes 
(5 × 106 cells) were cultured in RPMI 1640 medium with or without concanvalin A (Con A, 5 μg/ml) and lipopolysaccharide (LPS, 10 μg/ml) at 5% CO2, 
37ºC for 18 hours. TNF, tumor necrosis factor; IFN, interferon; IL, interleukin. IGT: impaired glucose tolerance; CON: normal rats with vehicle; NTZ: 
IGT rats with vehicle; NFB: IGT rats with fruiting bodies; NCM: IGT rats with submerged culture mycelium; NGX: IGT rats with acidic polysaccharide 
glucuronoxylomannan
healthy subjects. However, recent evidence suggested that type 2 
DM patients had impaired cell‑mediated immunity as shown in the 
insufficient lymphocyte proliferation in PBLs.[27,28] In the present 
study, IGT rats had a significant decreased proliferative response 
in Con A‑stimulated splenocytes [Figure 3b], with no significant 
changes in the percentages of T and B cells in PBLs [Table 2], 
whereas the percentages of Th splenocytes were significantly 
elevated. Whether this IGT‑induced increase in Th splenocytes 
is a compensative reaction in response to the decreased T‑cell 
proliferation deserves further investigation.
We also found that TNF‑α production of spontaneous (un‑
stimulated) and Con A‑ and LPS‑stimulated PBLs was signifi‑
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cantly decreased in IGT rats [Table 3]. This decrease implies 
that IGT rats had decreased acute phase reaction and inefficient 
systemic monocytes, T‑lymphocytes, and natural killer cells. 
These changes may explain, at least partially, why IGT rats 
did not have significant changes in circulating cytokines as the 
type 1 DM rats did.[20] In terms of the splenic immunity, the Con 
A‑stimulated TNF‑α production [Table 4] and the spontaneous 
and Con A‑ and LPS‑stimulated IFN‑γ production were decreased 
in IGT rats compared to normal rats. These results suggest that 
IGT rats had impaired innate and T‑cell mediated immunity in 
the spleen.
It has been found that mushrooms have antihyperglycemic 
activities because they are low in energy and carbohydrate, have no 
fat and cholesterol, and are high in protein, vitamins, and minerals, 
as well as they have abundant high‑molecular‑weight compounds, 
such as, polysaccharides, and a number of low‑molecular‑weight 
metabolites, such as lectins, lactones, terpenoids, alkaloids, sterols, 
and phenolic substances.[29] Our studies showed that FB, CM, and 
GX derived from T. mesenterica had significant antihyperglycemic 
activities in type 1 DM[19] and IGT rats. For example, ingestion of 
FB, CM, and GX significantly improved the glycemic response 
in IGT rats as shown by the decreased blood glucose levels in 
2‑h postprandial period and OGTT response and AUC [Figure 1 
and Table 1].
Mushroom polysaccharides have various biological 
activities.[12‑17] Polysaccharides of Tremella fuciformis have been 
reported to augment T‑lymphocytes in the PBL proliferation and 
decrease the IL‑2 activities in mouse splenocytes in vitro.[12] 
Jeong et al.[30] compared the immune‑modulatory properties of 
exo‑ and endopolysaccharides extracted from seven mushroom 
species and showed that the exopolysaccharides of T. mesenterica 
may reduce IFN‑γ, IL‑2, IL‑4, and IL‑5 production in T‑lympho‑
cytes. In type 1 DM rats, FB from T. mesenterica may increase 
peripheral cell‑mediated immunity and CM may decrease pro‑
inflammatory and Th1 cytokine production.[20] In this study, FB, 
CM, and GX of T. mesenterica did not have significant impact on 
plasma TNF‑α, IFN‑γ, and IL‑6 concentrations and spontaneous 
and mitogen‑stimulated splenocytic proliferation in IGT rats. In 
contrast, ingestion of CM significantly decreased the percentages 
of Th lymphocytes in the PBLs and B‑splenocytes [Table 2]. 
These results reveal that the immune‑modulatory effects of 
Tremella polysaccharides are different within the species in the 
same genus.
When evaluating the abilities of monocytes, macrophages, and 
T‑cells by measuring TNF‑α production, we previously showed 
that CM of T. mesenterica significantly decreased proinflammatory 
and Th1 cytokine production by PBLs and increased their produc‑
tion by splenocytes in type 1 DM rats.[20] In IGT rats, we found 
that FB and CM ingestion significantly reversed the IGT‑induced 
decreases in unstimulated PBLs and Con A‑ and LPS‑stimulated 
PBLs [Table 3] and Con A‑stimulated splenocytes [Table 4] and 
further elevated the increases in unstimulated splenocytes. The 
acid polysaccharide, GX, significantly increased TNF‑α produc‑
tion in spontaneous and Con A‑stimulated PBLs. This altered 
cytokine production reveals that natural FB of T. mesenterica 
and its submerged culture mycelia and acid polysaccharides may 
elevate systemic innate immunity in IGT rats.
The IGT‑decreased production of IFN‑γ, a Th1 cytokine im‑
portant for macrophage activation and critical for innate and adap‑
tive immunity, in Con A‑simulated splenocytes was significantly 
reversed by CM and GX, and this decrease in LPS‑stimulated 
splenocytes was significantly increased approximately fivefold by 
GX. However, IGT‑induced decrease in unstimulated splenocytes 
was further decreased by FB, CM, and GX. These results imply 
that T. mesenterica may inactivate T‑splenocytes in normal con‑
dition and the submerged culture mycelia, especially the acidic 
polysaccharides, may improve IGT‑induced impairment in T‑cell 
mediated immunity when splenocytes are stimulated.
IL‑6, a cytokine, acts as both pro‑ and anti‑inflammatory cy‑
tokine, and is secreted by T cells and macrophages to stimulate 
immune response. T. mesenterica did not affect the IL‑6 reduction 
of PBLs and splenocytes in type 1 DM rats.[20] In the present study, 
the IGT‑induced decrease in IL‑6 production in monocytes was 
significantly reversed by GC. In addition, ingestion of FB and GX 
significantly increased the spontaneous and Con A‑stimulated IL‑6 
production in PBLs. In terms of tissue‑specific immunity, IL‑6 
production in macrophages was increased twofold by CM and 
that in T‑splenocytes was increased fourfold by GX. The elevated 
IL‑6 production implies that T. mesenterica may increase innate 
and T‑cell immunity in IGT rats.
In the present study, rats orally consumed approximately 
250 mg/day of T. mesenterica, i.e., 1 g/kg body weight/day for 
28 days. This dose corresponds to the recommended daily human 
dose which is 9.7 g in a person weighing 60 kg. These results sug‑
gest that 1000 mg/kg of T. mesenterica FB, CM, and GX could 
be categorized as no‑observed‑adverse‑effect level (NOAEL) 
products, as it acts harmlessly under the current normal usage.
The present study has several limitations. First, the etiology of 
IGT induced by nicotinamide and STZ in rats is not the same as that 
in patients. Even though the gene knockout rat models are better 
than the chemical‑induced models, the price and the source of the 
animals are not feasible for most of the researchers. Therefore, 
we used this chemical‑induced animal model, as these rats had 
increased blood glucose in the postprandial and OGTT periods. 
The glycemic response is similar to that of IGT subjects. Second, 
we only performed this study for 14 days. Thus, we might have 
overlooked the long‑term effects of T. mesenterica. This might 
explain partially why those rats did not have significant changes 
in plasma cytokines as shown in other studies. Third, we did not 
investigate the mechanisms of T. mesenterica in modulating sys‑
temic and splenic immunity. In this study, we could only show 
the changes and profiles of the immunocytic subsets and cytokine 
production. It is of interest to elucidate the detailed mechanisms of 
T. mesenterica in regulating splenocytic proliferation and activat‑
ing the functions of PBLs and splenocytes.
In summary, the results presented here confirm that IGT is 
associated with elevation in Th splenocytes and suppression in 
proliferation of T‑splenocytes, TNF‑α production of PBLs, and 
IFN‑γ production of splenocytes. Ingestion of FB, CM, and GX 
improved hyperglycemia and reversed the IGT‑decreased periph‑
eral and splenocytic innate immunities. In addition, CM and GX 
reversed IGT‑decreased T‑cell mediated immunity in splenocytes 
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and GX increased IL‑6 production in PBLs and splenocytes. Taken 
together, our findings reveal that FB, CM, and acidic polysaccha‑
ride GX of T. mesenterica may increase innate and T‑cell mediated 
immunity via the elevation of proinflammatory and Th cytokine 
production in rats with IGT. The improvement in glycemic re‑
sponse and the elevation in innate and T‑cell mediated immunity 
suggest that T. mesenterica may be used as an adjuvant treatment 
in subjects with IGT to prevent or to delay the onset of type 2 DM.
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